Loading the session
Loading the session
Loading instrument
$3.42
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:32 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: −9.0% (SPY −1.6%). 3 months: −64.8% (SPY −0.4%). 1 year: −83.3% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: SCNX, SPY · as of 4 Nov 2026
Closed at $3.42 on 4 Nov 2026: 82.4% below the 52-week high of $19.47 (12 Nov 2025) and 29.5% above the low of $2.64 (23 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
The 4 Nov 2026 close of $3.42 was 41.8% below its 50-day average ($5.88) and 62.2% below its 200-day average ($9.04). It has closed below the 200-day for 53 sessions, since 21 Aug 2026.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
105.9K shares were sold short at the 15 Oct 2026 settlement, 6.0% of the 1.8M shares outstanding; covering them would take 1.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
October 23, 2025
+354.94%August 14, 2025
−45.50%March 17, 2025
+66.44%